Print Print   Email Email

The investor pages that follow are your resource for financial information about Medivation, Inc.

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat critically ill patients with serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers.

Recent Releases

Jan 17, 2012
Medivation and Pfizer Announce Results from Phase 3 Concert Trial of Dimebon in Alzheimer's Disease

Jan 9, 2012
Data From Phase 3 AFFIRM Trial of MDV3100 in Advanced Prostate Cancer to Be Highlighted in Late-Breaking Presentation at ASCO GU

more »

Investor and Media Contacts

For Investors
investors@medivation.com

For Media
media@medivation.com